Table 2 HPV negative conversion rates after Hiporfin-PDT in treating HSIL of the female lower reproductive tract.
HPV negative conversion rates | Percentage |
|---|---|
CHSIL | |
3–6 months | 74.5% (41/55) |
12 months | 89.1% (49/55) |
24 months | 89.8% (44/49) |
36 months | 95.8% (23/24) |
VaHSIL | |
3–6 months | 28.0% (7/25) |
12 months | 52.0% (13/25) |
24 months | 60.9% (14/23) |
36 months | 64.7% (11/17) |
Multiple sites of female lower genital tract HSIL | |
3–6 months | 18.2% (2/11) |
12 months | 45.5% (5/11) |
24 months | 60.0% (6/10) |
36 months | 62.5% (5/8) |
